00:00:06
Mechanism
recounts GLP-1 discovery/origin.
Review topic: GLP-1 history.
Checked against: Primary-source record still needed
original discovery papers.
Video claim watch
How Do Ozempic, Mounjaro & Other GLP-1 Agonists Work? | Dr. Zachary Knight & Dr. Andrew Huberman
Huberman Lab discussion on GLP-1 mechanism with neuroscience perspective.
Huberman Lab Clips channel15:00 runtime204K views when checked
Transcript review
5 material claims logged
Published with source gaps audit stateauto-captioned transcript0 operational-guidance flags3 source gaps
Reviewed Jul 12, 2026. Next review Aug 12, 2026.
useful mechanism explainer; verify historical and causal claims.
auto-caption available; 8 creator chapters.
Claim-by-claim audit
What the video says, and what needs checking
00:01:35
Mechanism
explains the incretin effect.
Review topic: glucose physiology.
Checked against: Primary-source record still needed
human incretin studies.
00:02:58
Regulatory contextEvidence scope
discusses GLP-1 in diabetes treatment.
Review topic: approved indications.
Checked against: Wegovy prescribing information
00:05:52
High-risk evidence claim
attributes weight-loss breakthroughs to longer-acting GLP-1 drugs.
Review topic: pharmacology / efficacy.
Checked against: Once-weekly semaglutide in adults with overweight or obesity
00:10:47
High-risk mechanism claim
discusses brain mechanisms for appetite/food valuation.
Review topic: CNS mechanism.
Checked against: Primary-source record still needed
human mechanistic studies; distinguish from rodent neurocircuitry.
Source check
Records used in this claim audit
Wegovy prescribing information
FDA prescribing information for Wegovy.
7 linked pagesOpen original ·
fda-wegovy-label-2025Once-weekly semaglutide in adults with overweight or obesity
Randomized STEP 1 trial of semaglutide in adults with overweight or obesity.
6 linked pagesOpen original ·
nejm-semaglutide-step1-2021-video